MFN News Items – iZafe Group

iZafe lanserar exklusivt aktieägarerbjudande – få en Dosell med kostnadsfritt abonnemang

iZafe Group introducerar nu ett nytt exklusivt förmånserbjudande för aktieägare. Alla som äger aktier i iZafe till ett värde av minst 50 000 kronor erbjuds en kostnadsfri Dosell med 100 % rabatt på abonnemanget.

Syftet med erbjudandet är att belöna lojalitet och samtidigt ge fler möjlighet att uppleva nyttan av Dosell – en läkemedelsautomat som bidrar till ökad trygghet och följsamhet i medicinering.

Erbjudandet tillhandahålls genom iZafes helägda dotterbolag Dosell AB.

Villkor i korthet:

Gäller för privatpersoner som äger aktier i iZafe Group AB (publ) för minst 50 000 kronor
Aktievärdet baseras på senast tillgängliga stängningskurs
Erbjudandet gäller en (1) Dosell med kostnadsfritt abonnemang
Gäller så länge aktieinnehavet uppgår till minst 50 000 kronor
Gäller endast för leveranser inom Sverige

För mer information och anmälan: https://dosell.se/aktieagarforman/

Vi ser detta som ett naturligt steg i vår ambition att både öka värdet för våra aktieägare och sprida användningen av Dosell i samhället.

Om iZafe Group AB (publ.)

iZafe Group är ett Life Science bolag som bedriver forskning, utveckling och marknadsföring av digitala medicinska lösningar och tjänster för tryggare läkemedelshantering i hemmet.

Bolaget leder utvecklingen av digital läkemedelsdispensering genom läkemedelsroboten Dosell samt SaaS-lösningen och den uppkopplade dosettasken Pilloxa. Bolagets lösningar minskar risken för felmedicinering i hemmet, ökar följsamheten, avlastar den offentliga vården, ökar livskvaliteten för patienter samt skapar en tryggare miljö för anhöriga.

Kunderna utgörs av privatpersoner, läkemedelsbolag samt offentliga och privata vårdgivare i Sverige, Norden och globalt. iZafe Group säljer primärt via väletablerade partners som redan besitter långa och djupa kundrelationer med de prioriterade kundgrupperna. Huvudkontoret ligger i Stockholm.

iZafe Group AB är noterat på Nasdaq First North Growth Market sedan 2018. Bolagets Certified Adviser är DNB Carnegie Investment Bank AB. Ytterligare information finns på www.izafegroup.com

iZafe lanserar exklusivt aktieägarerbjudande – få en Dosell med kostnadsfritt abonnemang

100512242 Dosell Lkemedelsautomat

iZafe Group resolves on a directed share issue of approximately SEK 10 million

iZafe Group AB (publ) ("iZafe" or the "Company") announces today that the Board of Directors has resolved, based on the authorization granted by the Annual General Meeting on May 28, 2025, on a directed share issue of 43,478,261 Class B shares at a subscription price of SEK 0.23 per share, with deviation from the shareholders' preferential rights (the "Directed Share Issue"), to external investors as well as a number of existing shareholders. The subscription price corresponds to a discount of approximately 11.5 percent compared to the closing price on Nasdaq First North Growth Market on June 26, 2025. Through the Directed Share Issue, iZafe will receive gross proceeds of approximately SEK 10 million before issue-related costs.

“Over the past six months, we have taken important steps that strengthen our market position – with clear growth in both Sweden and the Netherlands as well as strong demand from additional markets. At the same time, we are seeing a multiplied revenue and a steady increase in active units. By now raising new capital from both long-term shareholders and new investors, we ensure that we can continue to develop the business at a high pace and deliver according to the plan we have clearly communicated. This share issue is a sign of strength and a result of the trust that has been built – not only in our product portfolio, but also in the team, our strategy, and the market potential ahead. We are convinced that this step benefits all shareholders and lays the foundation for continued growth and value creation,” comments Anders Segerström, CEO of iZafe Group AB.

The Directed Share Issue
The Directed Share Issue comprises 43,478,261 Class B shares and has been resolved by the Board of Directors based on the authorization granted by the Annual General Meeting held on May 28, 2025. The right to subscribe for shares in the Directed Share Issue is granted to external investors and a number of existing shareholders. The subscription price is SEK 0.23 per share, representing a discount of approximately 11.5 percent compared to the closing price on Nasdaq First North Growth Market on June 26, 2025. The subscription price has been determined through arm’s length negotiations with external investors in the Directed Share Issue, in consultation with the Company’s financial advisor Stockholm Corporate Finance AB, and based on an analysis of several market factors. The Directed Share Issue also enables the Company to capitalize on the current interest in the Company’s shares among the subscribers at a price in line with the prevailing market price. The Board of Directors therefore assesses that the subscription price has been determined on market terms considering current market conditions. Through the Directed Share Issue, the Company will receive approximately SEK 10 million before transaction-related costs, which are estimated to amount to approximately SEK 0.29 million. The subscribers in the Directed Share Issue include both existing long-term shareholders of the Company – Eva Redhe, Gästrike Nord Invest AB, Stefan Wård, Filippa Landström, Junior Farma S.L. and Massimiliano Franzé – and new shareholders Erik Dahlberg, Rustan Panday, and Olle Olsson.

Background and Rationale for the Directed Share Issue
The purpose of the Directed Share Issue is to finance accelerating growth, execute strategic investments, and strengthen liquidity to enable repayment of an existing loan including interest, amounting to SEK 5.7 million, from Exelity AB. The remaining capital, approximately SEK 4.3 million before issue-related costs, strengthens iZafe’s working capital and ensures greater capacity to meet the clearly increasing demand for Dosell in existing and new markets.

Deviation from the Shareholders’ Preferential Rights
The purpose of the Directed Share Issue and the reason for the deviation from the shareholders’ preferential rights is to carry out a capital raise in a time- and cost-efficient manner. The Board has evaluated the possibility of primarily conducting a rights issue. The Company has weighed the advantages and disadvantages of a rights issue compared to a directed share issue and concluded that a rights issue (i) would be significantly more time-consuming and may risk the Company missing potential growth opportunities, (ii) would result in considerably higher issue-related costs, primarily due to the procurement of a guarantee consortium and legal fees, (iii) would expose the Company to greater market volatility, and (iv) would likely need to be conducted at a lower subscription price and result in higher dilution, which would disadvantage all shareholders. In addition, a rights issue would not provide the Company with capital in time to repay short-term debt financing, thus impairing the ability to meet such obligations. The Directed Share Issue also allows the Company to take advantage of current investor interest in its shares at a price aligned with the prevailing market price. Given the above and after careful consideration, the Board assesses that the Directed Share Issue is the most favorable financing option for iZafe and in the best interest of both the Company and its shareholders, and therefore also justifies a deviation from the main rule of shareholders’ preferential rights. The subscription price in the Directed Share Issue has been determined through arm’s length negotiations with the new external investors, based on the prevailing share price of the Company’s Class B shares. Furthermore, the Board has ensured the market-based nature of the subscription price in consultation with financial advisors, based on current market conditions and previously indicated price levels in discussions with potential investors. In the Board’s assessment, the market terms of the price have thus been confirmed through this process. The reason for including existing shareholders in the Directed Share Issue is partly that this was part of the negotiation with the new external investors, and partly because the Board deemed it strategically wise to include these long-term and committed shareholders in the Directed Share Issue – to help strengthen the credibility and trust in the Company on the market, for the benefit of all shareholders.

Number of Shares, Share Capital, and Dilution
Through the Directed Share Issue, the Company’s share capital will increase by SEK 2,173,913.05, from SEK 16,086,808.55 to SEK 18,260,721.60, through the issuance of 43,478,261 Class B shares. This means that the total number of shares will increase from 321,736,171 to 365,214,432 shares, of which 600,000 are Class A shares carrying ten (10) votes per share at the general meeting, and 364,614,432 are Class B shares carrying one (1) vote per share. The Directed Share Issue entails a dilution of approximately 11.9 percent of the share capital for existing shareholders, calculated as the number of Class B shares issued in the Directed Share Issue divided by the total number of shares in the Company after the share issue.

Advisors
Stockholm Corporate Finance is acting as financial advisor and LW Advisory as legal advisor to iZafe in connection with the Directed Share Issue. Aqurat Fondkommission is acting as issuing agent in connection with the Directed Share Issue.

Important Information
The publication, release, or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions and persons in jurisdictions where this press release has been published or distributed must inform themselves of and comply with such legal restrictions. Recipients of this press release are responsible for using it and the information contained herein in accordance with applicable rules in their respective jurisdictions. This press release does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for any securities issued by the Company in any jurisdiction where such offer or solicitation would be unlawful or would require additional registration or other measures.

This press release does not constitute an offer to buy or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States without registration under, or an exemption from, the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced, or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, Russia, Belarus, or any other jurisdiction where such announcement, publication, or distribution would be contrary to applicable regulations or would require additional registration or other measures than those required under Swedish law. Any failure to comply with this instruction may constitute a violation of the Securities Act or applicable securities laws in other jurisdictions.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. The Company has not approved any offer to the public of securities in any EEA member state and no prospectus has been or will be prepared in connection with the Directed Share Issue. In each EEA member state, this communication is only addressed to “qualified investors” in that member state as defined in the Prospectus Regulation.

This press release does not identify or purport to identify the risks (direct or indirect) that may be associated with an investment in the new shares. Any investment decision to acquire or subscribe for new shares in the Directed Share Issue must be made solely based on publicly available information, which has not been independently verified by the financial advisor.

This press release does not constitute a recommendation concerning any investor’s decision regarding the Directed Share Issue. Each investor or potential investor should conduct their own investigation, analysis, and evaluation of the business and information described in this press release and all publicly available information. The price and value of securities can decrease as well as increase. Past performance is not an indication of future performance. Neither the content of the Company’s website nor any other website accessible through hyperlinks on the Company’s website is incorporated into or forms part of this press release.

Failure to comply with these instructions may constitute a violation of the Securities Act or applicable laws in other jurisdictions.

Forward-looking Statements
This press release contains forward-looking statements that reflect the Company’s intentions, beliefs, or current expectations regarding and targets for the Company’s future operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies, and opportunities, as well as the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and can be identified by words such as “believe,” “expect,” “anticipate,” “intend,” “may,” “plan,” “estimate,” “will,” “should,” “could,” “aim” or “might,” or, in each case, their negative or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which in turn are based on additional assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, actual results or outcomes could differ materially from those described in the forward-looking statements. Such risks, uncertainties, contingencies, and other important factors could cause actual events to differ materially from the expectations expressed or implied by the forward-looking statements in this press release. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are error-free and accepts no responsibility for the future accuracy of the opinions expressed in this press release or any obligation to update or revise the statements in this press release to reflect subsequent events. The information, opinions, and forward-looking statements contained in this press release speak only as of its date and may be subject to change without notice. The Company undertakes no obligation to review, update, confirm, or release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. The company’s Certified Adviser is DNB Carnegie Investment Bank AB. Further information is available at www.izafegroup.com

iZafe Group resolves on a directed share issue of approximately SEK 10 million

Affärer Partners

Monthly Update May – Surpassing 1,000 Units and Growing Strategic Partnerships

May has been an eventful month where we took yet another important step forward. The number of active billable Dosell units increased by an additional 14% from April – a growth now built on an ever-larger base volume. At the same time, we passed a major symbolic milestone: more than 1,000 active units in operation, showing that we’ve made it through the most challenging phase – building a stable, scalable, and in-demand solution.

Growth is driven both by more municipalities and partners starting to use Dosell – and by existing customers prescribing more units per client. We are seeing broad and growing traction, even though we’re still coming from relatively modest volumes. That makes the strength of our growth rate all the more encouraging.

We are now entering the summer months, which traditionally means a somewhat slower pace due to holidays. But we look forward to ramping up again in the fall – firmly anchored in our long-term strategy.

Sweden: Growth in VGR and Increasing Demand Ahead of Autumn
In May, two more municipalities in the Västra Götaland region (VGR) began using Dosell, bringing our presence in the region to 14 municipalities. Several of these have started increasing their internal volumes and are receiving very positive feedback from both staff and users.

Two new municipalities have approved pilot projects with Dosell set to start right after summer. We’ve also held numerous presentations for municipalities now considering launching their own pilots – a clear sign of the strong momentum we’re experiencing in the Swedish public care sector.

At Vitalis, the Nordic region’s leading event for health and social care, we gained strategic traction – both through our presence and by presenting collaborations with Tamro, JDM Innovation, and Phoenix Group. The reaction from visitors was overwhelmingly positive, summarized best by the comment: “Finally, two solutions in one system!”

Especially appreciated was our joint stage appearance with ATEA and Ulricehamn Municipality, where Ulricehamn shared their successful implementation and how their “slow and steady” approach has led to stable, positive development. Many home care teams in the municipality are now reaching out, eager to start using Dosell themselves.

We also participated in Senior Day in Kungsträdgården, where we received great interest in our consumer solution. At the same time, our partner Zafe exhibited at the Dementia Days event, where Dosell attracted significant attention for its value in early intervention for cognitive impairment. The new Social Services Act emphasizes this very need – and many now see Dosell as a key part of the solution.

Spain: Pharmacy Network and Interest from Private Care Providers
In Spain, our partner Ti Medi continues rolling out Dosell through the national pharmacy network, which includes over 1,500 pharmacies.

Following strong media attention in April, private care providers have also started to show interest in Dosell. Our B2B solution is now being actively presented to these providers, who see the opportunity to complement their existing care structures with a digital solution that enhances independence and safety in medication management.

The Netherlands: Continued Growth and Trade Fair Momentum
In the Netherlands, growth continues at a rapid pace. Our customer TCCN is highly engaged and has established an efficient approach for broad outreach – already leading to concrete meetings with new stakeholders. At the same time, their existing customers are increasing their volumes month over month.

Dosell TV has generated strong interest, and our presence at the April trade fair served as a clear catalyst for new contacts. Several of these are now in the quotation or implementation phase. The combination of proactive sales, a strong network, and a value-driven offering that meets real needs gives us excellent conditions for continued expansion together with TCCN.

Strategic Partnership – LOI with JDM Innovation
In May, we signed a Letter of Intent with JDM Innovation, aiming to establish a strategic partnership in Europe. JDM is a well-established player in logistics, automation, and medical technology, working with both international pharmaceutical companies and pharmacy chains.

The partnership creates opportunities to integrate our technologies and opens doors to new markets in Europe. Discussions around joint pilots are already underway, and we see great potential in driving efficiency and safe medication management together in new markets.

Celebrate the 1,000-Unit Milestone with Us – Investor Evening June 12
To mark our achievement of surpassing 1,000 active units, we’re inviting you to an investor evening in Stockholm – on Thursday, June 12.

We sincerely hope as many shareholders as possible will take this opportunity to come, meet our team in person, ask questions, and get deeper insight into our journey and future vision. It’s a great chance to connect – and to experience Dosell live.

Welcome – we look forward to seeing you! Register here: https://forms.office.com/e/8qHzwLu5S8

Thank You for Your Trust – Together We Are Shaping the Future of Medication Management
iZafe Group is in a phase of strong commercial momentum. May’s results confirm both the direction and pace of our progress. We’re strengthening our partnerships, expanding our network, and building on a model that has now proven both scalable and effective.

Thank you for following our journey – and we warmly welcome you to the investor evening on Thursday, June 12.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

Monthly Update May – Surpassing 1,000 Units and Growing Strategic Partnerships

Business Partners 6

Dosell Reaches 1,000 Units in Operation – Celebrates Milestone with Investor Event in Stockholm

iZafe Group AB (publ) (“iZafe” or “the Company”) today announces that its subsidiary Dosell has reached a significant milestone: more than 1,000 active Dosell units are now in use across Europe. This marks a clear breakthrough for safe and digital medication management in the home.

To celebrate this achievement, the company invites shareholders, partners, healthcare professionals and other stakeholders to an exclusive event at its Stockholm office on June 12.

“This milestone is both personal and strategic. Reaching 1,000 Dosell units in operation proves that we’ve made it through the most challenging phase – building a stable, scalable and in-demand solution. Now we’re ready to grow in earnest. None of this would have been possible without the tremendous dedication of our team, our partners, and our shareholders who believed in us every step of the way. I look forward to sharing the next chapter with you,” says Anders Segerström, CEO of iZafe Group.

During the evening, we will share the journey toward reaching 1,000 active Dosell units – the challenges we’ve faced, the key turning points, and why this moment represents a breakthrough for both our company and the digital healthcare sector.

You’ll also get a glimpse of what’s coming next – our strategic goals, technical roadmap, and how we plan to scale up the business both in Sweden and internationally.

Food and drinks will be served in a relaxed setting where you’ll have the opportunity to connect with the Dosell team, fellow shareholders, healthcare innovators, and industry professionals.

Event Details:

Date: Wednesday, June 12
Time: From 6:00 PM
Location: iZafe Group HQ, David Bagares Gata 3A, Stockholm
Registration: https://forms.office.com/e/8qHzwLu5S8

Please note that registration is required and space is limited – spots will be allocated on a first-come, first-served basis.

About Dosell
Dosell is a medical technology solution that ensures the right person takes the right medication at the right time. The product is specifically designed to prevent double dosing and improve adherence – one of the greatest challenges in modern healthcare. Dosell is currently used by municipalities, private care providers and partners across Europe.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

Dosell Reaches 1,000 Units in Operation – Celebrates Milestone with Investor Event in Stockholm

Dosell 1000

Kommuniké från årsstämma i iZafe Group AB

Årsstämman i iZafe Group AB, orgnr. 556762-3391, (”Bolaget”) ägde rum torsdagen den 28 maj 2025 på Bolagets kontor. Årsstämman beslutade, bland annat följande:

Fastställande av resultat- och balansräkning
Fastställande av resultat- och balansräkning för moderbolaget och koncernen för räkenskapsåret 2024.

Utdelning
Stämman beslutade att ingen utdelning lämnas och att årets resultat balanseras i ny räkning.

Styrelse och revisor
Stämman beviljade styrelseledamöterna och verkställande direktören ansvarsfrihet för räkenskapsåret 2024.

Stämman beslutade att styrelsen ska bestå av fyra ordinarie ledamöter utan suppleanter. Stämman beslutade om omval av Richard Wolff till styrelseordförande samt om omval av Jenny Styren till ordinarie styrelseledamot. Stämman beslutade om nyval av Anna Håkansson och Samuel Danofsky till styrelseledamöter. Den auktoriserade revisorn Johan Kaijser omvaldes till Bolagets revisor för tiden intill slutet av nästa årsstämma.

Styrelse- och revisorsarvode
Stämman fastställde styrelsearvode med 117 600 kronor och arvode till styrelseordförande med 176 400 kronor. Alla ersättningar som en styrelseledamot erhåller från Bolaget i enhetlig med godkända uppdragsavtal kan avräknas mot styrelsearvodet. Arvode till revisorn ska utgå enligt godkänd räkning.

Bemyndigande för styrelsen att fatta beslut om emission av aktier, teckningsoptioner och konvertibler
Stämman fastställde att bemyndiga styrelsen att – vid ett eller flera tillfällen och längst intill nästkommande årsstämma – besluta om att öka Bolagets aktiekapital genom nyemission av aktier samt att emittera teckningsoptioner och konvertibler motsvarande högst tjugo (20) procent av det totala antalet utestående aktier i Bolaget vid den tidpunkt då styrelsen första gången utnyttjar bemyndigandet. Nyemission av aktier eller emission av teckningsoptioner eller konvertibler ska ske till marknadsmässiga villkor och ska kunna ske med eller utan företrädesrätt för aktieägarna samt med eller utan bestämmelse om apport, kvittning eller andra villkor.

Ändring av bolagsordningen samt minskning av aktiekapitalet för avsättning till fritt eget kapital
Stämman beslutade om ändring av bolagsordningens gränser för aktiekapitalet från lägst 50 000 000 kronor och högst 200 000 000 kronor till lägst 15 000 000 kronor och högst 60 000 000 kronor, samt om minskning av aktiekapitalet med 46 527 925,65 kronor för avsättning till fritt eget kapital. Minskningen av aktiekapitalet sker utan indragning av aktier. Efter minskningen av aktiekapitalet kommer Bolagets aktiekapital att uppgå till 15 509 308,55 kronor, fördelat på sammanlagt 310 186 171 aktier, varav 600 000 A-aktier som ger rätt till tio (10) röster per aktie på bolagsstämma och 309 586 171 B-aktier som ger rätt till en (1) röst per aktie på bolagsstämma. Samtliga aktier kommer efter minskningen att ha ett kvotvärde om 0,05 kronor per aktie. Beslutet om minskning av aktiekapitalet kräver tillstånd från Bolagsverket eller allmän domstol.

Om iZafe Group AB (publ.)

Kommuniké från årsstämma i iZafe Group AB

Affärer Partners

iZafe signs Letter of Intent with JDM Innovation with the goal to initiate a strategic partnership in Europe

iZafe Group AB (publ) (“iZafe” or “the Company”) today announces that it has signed a Letter of Intent (LOI) with German company JDM Innovation GmbH, part of the PHOENIX group. The goal is to initiate a strategic partnership where the Dosell medication robot will be integrated with JDM’s dispensing solution Smila into a joint digital platform for home-based medication management. The solution is aimed at municipalities and care providers across Europe and is designed to simplify implementation, increase adherence, and free up valuable time in healthcare delivery.

JDM has more than 40 years of experience in digital healthcare solutions and is the developer of Smila – an automatic medication dispenser already in use in Finland and Denmark. In Sweden, Smila is being introduced in collaboration with Tamro AB. The PHOENIX group, to which both JDM and Tamro belong, is the European leader in pharmaceutical wholesale, pharmacy retail, and services for the pharmaceutical industry with operations in 29 healthcare markets, providing a strong foundation for European expansion.

Dosell, developed by iZafe, is a Swedish medication robot used in elder care to ensure safe and accurate medication intake at home. The solution is currently established in a growing number of municipalities in Sweden and care organizations in the Netherlands and Spain, with increasing interest from other European markets. The technology has proven to reduce medication errors, enhance patient safety, and save valuable time for healthcare staff – making it possible to deliver high-quality care to more individuals.

Through this partnership, two complementary solutions are brought together in one integrated platform. Municipalities and care providers gain access to a unified system where a single training and technical integration unlock two proven technologies – streamlining procurement, implementation, and day-to-day use.

“This is an important strategic step for iZafe. By combining our solution with Smila and leveraging PHOENIX group’s strong presence in Europe, we are creating new opportunities for growth. Together, we are making it easier for municipalities and care providers to deliver safe and effective medication management to more users,” says Anders Segerström, CEO of iZafe Group.

Both iZafe and JDM advocate that different users have different needs. With this new platform, municipalities can easily offer tailored solutions based on each user’s abilities – without compromising on safety or ease of use. The platform ensures smooth implementation and effective daily operations, helping staff save time and enabling more people to receive high-quality care.

“Dosell is a perfect complement to Smila. Together, we can offer a strong end-to-end solution on one platform that simplifies the implementation of digital medication management for municipalities across Europe,” says Martin Lafleur, CEO of JDM Innovation GmbH.

This week, Dosell will exhibit together with Tamro at Vitalis – the Nordic region’s leading event for the future of health, care, and welfare technology. The collaboration will be presented under the joint message: “Two brands. One vision. One platform.”

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe signs Letter of Intent with JDM Innovation with the goal to initiate a strategic partnership in Europe

JDM Smila Dosell

April Monthly Report – Continued Growth as We Approach 1,000 Active Units

April was a month marked by concrete expansion, deepened customer relationships, and sustained strong interest from new stakeholders. After a 12% increase in billable Dosell units in March, we grew by an additional 19% in April. This is a clear sign that our strategy is effective and that the need for digital medication management continues to rise. As it stands, we expect to reach an important milestone in May – 1,000 active billable units. This is a symbolically strong threshold that reflects both our momentum and that we are now truly beginning to scale.

Dosell continues to earn trust – both as a practical everyday tool and as a key enabler in the transition to future-oriented healthcare. Our momentum remains strong, and the interest from new municipalities and partners shows that the market is moving.

Sweden: Broad Implementation in VGR and Strong Demand
In April, two additional municipalities in the Västra Götaland Region (VGR) launched Dosell. In total, 12 municipalities in the region are now operational, and we’re seeing most of them move from pilot projects into broad implementation. This, in turn, has encouraged other municipalities – previously hesitant – to reach out and express interest in introducing Dosell.

We also conducted 10 demonstrations for municipalities currently evaluating pilot projects. One municipality launched a pilot in April, and the results so far have been very positive – no alerts have been triggered, and users report high satisfaction.

In addition, we are now engaged in exciting conversations with new potential partners who are highly interested in Dosell and its user-friendly design. We are in a phase where more stakeholders are recognizing both the need for and the potential of a solution that simplifies care, reduces strain, and empowers users.

We also participated in Seniors’ Day on May 6 in Stockholm’s Kungsträdgården – a gathering for over 60,000 seniors. We presented both Dosell and our consumer version and were met with strong interest from the target audience.
The overall development in Sweden demonstrates that our solution has gained a firm foothold and continues to grow organically through strong results and word-of-mouth.

The Netherlands: 21% Growth and New Clients from the Expo
In the Netherlands, our partner TCCN continues to deliver strong results. The number of active Dosell units increased by 21% from March to April, and the customer base is expanding.

Following the April expo, around 25 new leads were generated, leading to four meetings and one official offer. The first broadcast of Dosell TV also sparked significant interest, providing more organizations with insight into how Dosell works in practice.

The combination of satisfied end-users, innovative outreach, and a growing partner network provides a solid foundation for continued growth through the spring.

Spain: Market Launch and National TV Exposure
In Spain, Dosell has now entered the market through our partner Ti Medi and the Savioo Home concept. After participating in expos in Barcelona and France, we are now seeing increasing media coverage.

On April 26, Dosell appeared on Spanish national television in the program Aruser on La Sexta – one of the country’s largest TV channels. Host Alfonso Arús and his panel expressed strong support for the Savioo concept and emphasized the solution’s value for elderly individuals and those with complex medication routines. This provides clear proof that Dosell is gaining attention and credibility among the general public.

Over 50 pharmacies have shown interest in offering Savioo Home, which is now being launched nationally. We hope to see a tangible increase in sales in the coming months.

Dosell’s visibility in Spain strengthens our brand in a strategically important market and sets the stage for future volume growth.

To Our Shareholders – A Solid Foundation for Growth
iZafe Group remains in a development phase – but April clearly demonstrates that our strategy is bearing fruit. We are strengthening our position in Sweden through expanded cooperation in VGR, deepening our presence in Europe through new client relationships in the Netherlands, and reaching the general public in Spain through national TV.

At the same time, we are continuously engaging in new partnership discussions, and we see more readiness than ever to take action. The demand for safe, efficient medication management is growing rapidly – and Dosell is well positioned to meet that challenge.

Thank you for your continued trust and for following our journey forward.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. The company’s Certified Adviser is Carnegie Investment Bank AB (publ). Further information is available at www.izafegroup.com

April Monthly Report – Continued Growth as We Approach 1,000 Active Units

Pic News

iZafe Group AB har offentliggjort årsredovisning för 2024

iZafe Group AB (publ.) meddelar härmed att bolaget har offentliggjort sin årsredovisning för 2024.

Årsredovisningen bifogas samt finns tillgänglig på bolagets webbplats: https://izafe.se/investor-relations/#archive

Om iZafe Group AB (publ.)

iZafe Group är ett Life Science bolag som bedriver forskning, utveckling och marknadsföring av digitala medicinska lösningar och tjänster för tryggare läkemedelshantering i hemmet.

Bolaget leder utvecklingen av digital läkemedelsdispensering genom läkemedelsroboten Dosell samt SaaS-lösningen och den uppkopplade dosettasken Pilloxa. Bolagets lösningar minskar risken för felmedicinering i hemmet, ökar följsamheten, avlastar den offentliga vården, ökar livskvaliteten för patienter samt skapar en tryggare miljö för anhöriga.

Kunderna utgörs av privatpersoner, läkemedelsbolag samt offentliga och privata vårdgivare i Sverige, Norden och globalt. iZafe Group säljer primärt via väletablerade partners som redan besitter långa och djupa kundrelationer med de prioriterade kundgrupperna. Huvudkontoret ligger i Stockholm.

iZafe Group AB är noterat på Nasdaq First North Growth Market sedan 2018. Bolagets Certified Adviser är Carnegie Investment Bank AB (publ). Ytterligare information finns på www.izafegroup.com

Årsredovisning 2024 (1)

Business Partners 4

KALLELSE TILL ÅRSSTÄMMA I IZAFE GROUP AB

Aktieägarna i iZafe Group AB, org.nr 556762–3391 (”iZafe” eller ”Bolaget”), kallas härmed till årsstämma den 28 maj 2025 kl. 14:00 på Bolagets lokaler på David Bagares Gata 3, Stockholm. Inregistrering inleds från klockan kl. 13:45.

RÄTT ATT DELTA OCH ANMÄLAN

Aktieägare som önskar delta på bolagsstämman ska

dels vara införd i den av Euroclear Sweden AB förda aktieboken den 20 maj 2025,

dels senast den 22 maj 2025 anmäla sig för deltagande på stämman hos Bolaget via e-post till eller per post till David bagares gata 3 BV, 111 38 Stockholm, ”Årsstämma”. Vid anmälan ska aktieägaren uppge namn, person- eller organisationsnummer, adress, och telefonnummer samt, i förekommande fall, uppgift om biträde (högst 2).

FÖRVALTARREGISTRERADE AKTIER

Aktieägare som har låtit förvaltarregistrera sina aktier måste låta registrera sina aktier i eget namn per avstämningsdagen den 20 maj 2025 för att ha rätt att delta vid årsstämman. Sådan registrering kan vara tillfällig (s.k. rösträttsregistrering) och begärs hos förvaltaren enligt förvaltarens rutiner. Rösträttsregistreringar som genomförts (dvs. är registrerade hos Euroclear Sweden AB) senast den 22 maj 2025 beaktas vid framställningen av aktieboken.

OMBUD

Aktieägare som företräds genom ombud ska utfärda skriftlig, av aktieägaren undertecknad och daterad fullmakt för ombudet. Fullmaktens giltighetstid får vara högst fem år om det särskilt anges. Anges ingen giltighetstid gäller fullmakten högst ett år. Om fullmakten utfärdas av juridisk person ska kopia av registreringsbevis eller motsvarande för den juridiska personen bifogas.

Fullmakten i original samt eventuellt registreringsbevis bör i god tid före stämman insändas per brev till Bolaget på ovan angiven adress. Fullmaktsformuläret finns tillgängligt på Bolagets webbplats (www.izafegroup.com) senast tre veckor innan stämman.

FÖRSLAG TILL DAGORDNING

Stämmans öppnande
Val av ordförande vid stämman
Upprättande och godkännande av röstlängd
Godkännande av dagordningen
Val av en eller två justeringsmän
Prövning av om stämman blivit behörigen sammankallad
Föredragning av framlagd årsredovisning och revisionsberättelse samt koncernredovisning och koncernrevisionsberättelse
Beslut om

a. om fastställande av resultaträkning och balansräkning samt koncernresultaträkning och koncernbalansräkning;

b. om dispositioner beträffande Bolagets vinst eller förlust enligt den fastställda balansräkningen;

c. om ansvarsfrihet åt styrelsens ledamöter och verkställande direktör

Fastställande av antalet styrelseledamöter och revisorer samt suppleanter
Fastställande av styrelse- och revisorsarvoden
Val av styrelse och eventuella styrelsesuppleanter och revisorer och eventuella revisorssuppleanter
Beslut om bemyndigande för styrelsen att fatta beslut om emission av aktier, teckningsoptioner och konvertibler
Beslut om

ändring av bolagsordningen; samt
minskning av aktiekapitalet för avsättning till fritt eget kapital.

Beslut om bemyndigande till styrelsen att vidta mindre justeringar av de på stämman fattade besluten
Stämmans avslutande

FÖRSLAG TILL BESLUT

Punkt 2 – Val av ordförande vid stämman

Valberedningen föreslår att stämman väljer Richard Wolff till ordförande vid bolagsstämman eller, vid förhinder, sådan annan person som styrelsen anvisar.

Punkt 8b – Beslut om disposition beträffande Bolagets vinst eller förlust enligt den fastställda balansräkningen

Styrelsen föreslår att samtliga till årsstämmans förfogande stående medel överförs i ny räkning.

Punkt 9–11 – Val av styrelse och eventuella styrelsesuppleanter samt i förkommande fall revisorer och eventuella revisorssuppleanter, fastställande av styrelse- och revisorsarvoden, val av styrelse och eventuella styrelsesuppleanter samt revisor och eventuella revisorssuppleanter

Valberedningen föreslår följande:

att styrelsen ska bestå av fyra ledamöter utan suppleanter. Antalet revisorer ska uppgå till en auktoriserad revisor utan suppleanter.
att ersättning till vardera styrelseledamoten ska utgå med 117 600 kronor (motsvarande 2 prisbasbelopp) och ersättning till styrelseordförande med 176 400 kronor (motsvarande 3 prisbasbelopp). Alla ersättningar som en styrelseledamot erhåller från Bolaget i enlighet med godkända uppdragsavtal kan avräknas mot styrelsearvodet.
att arvode till revisorn ska utgå enligt godkänd räkning.
omval av Jenny Styren och Richard Wolff som ordinarie styrelseledamöter. Göran Hermanson och Magnus Engman har avböjt omval.
nyval av Anna Håkansson och Samuel Danofsky till ordinarie styrelseledamöter.
omval av Richard Wolff som styrelseordförande.
omval av den auktoriserade revisorn Johan Kaijser på LR Revision och Redovisning Sverige AB för tiden intill slutet av årsstämman 2026.

Anna Håkansson

Anna har en mångårig och bred erfarenhet från offentlig sektor, bland annat som stadsdirektör, CFO och interimchef i flera stora organisationer. Hon har även haft uppdrag i flera pensionsstiftelser och styrelser, där hon kombinerat operativt och strategiskt ansvar. Anna är en nyfiken och resultatdriven ledare som brinner för utveckling och effektiv styrning.

Yrkeserfarenhet: Tf ekonomichef i Solna stad sedan 2023. Tidigare biträdande stadsdirektör i Stockholms stad samt stadsdirektör och CFO i Sundbybergs stad. Lång erfarenhet som finanschef i både privat och offentlig sektor.

Utbildning: Utbildad i redovisning vid Southern Illinois University, Carbondale. Styrelseutbildning från Styrelseakademien.

Annas omfattande bakgrund inom ekonomi, offentlig förvaltning och ledarskap gör henne till ett starkt tillskott i vår styrelse.

Samuel Danofsky

Samuel har lång erfarenhet inom kommunikation, politisk påverkan och opinionsbildning, särskilt inom hälso- och sjukvårdssektorn. Han har arbetat både operativt och strategiskt, såväl som rådgivare till regeringen och i ledande roller inom näringslivet. Med sin förmåga att bygga förtroende och driva komplexa kommunikationsfrågor är Samuel en värdefull förstärkning till styrelsen.

Yrkeserfarenhet: Kommunikationschef på Unilabs. Tidigare kommunikationschef på Kry samt senior rådgivare på JKL och Hallvarsson & Halvarsson. Har även varit politisk rådgivare i riksdagen och på Regeringskansliet.

Utbildning: Kandidatexamen i nationalekonomi och statsvetenskap från Uppsala universitet. Studier vid University of Michigan.

Samuels djupa förståelse för kommunikation, politik och vårdsektorns komplexitet gör honom väl rustad att bidra till vår strategiska utveckling.

Punkt 12 – Beslut om bemyndigande för styrelsen att fatta beslut om emission av aktier, teckningsoptioner och konvertibler

Styrelsen föreslår att årsstämman beslutar att bemyndiga styrelsen att – vid ett eller flera tillfällen och längst intill nästkommande årsstämma – besluta om att öka Bolagets aktiekapital genom nyemission av aktier samt att emittera teckningsoptioner och konvertibler motsvarande högst tjugo (20) procent av det totala antalet utestående aktier i Bolaget vid den tidpunkt då styrelsen första gången utnyttjar bemyndigandet.

Nyemission av aktier, liksom emission av teckningsoptioner och konvertibler, ska kunna ske med eller utan avvikelse från aktieägarnas företrädesrätt samt med eller utan bestämmelse om apport, kvittning eller andra villkor. Enligt 16 kap. aktiebolagslagen äger styrelsen inte med stöd av detta bemyndigande besluta om emissioner till styrelseledamöter i koncernen, anställda med flera.

Emission beslutad med stöd av bemyndigandet ska ske till marknadsmässiga villkor (varmed bland annat avses att marknadsmässig emissionsrabatt får lämnas) och betalning ska, förutom kontant betalning, kunna ske med apportegendom eller genom kvittning, eller eljest med villkor. Emission beslutad med stöd av bemyndigandet ska ske i syfte att tillföra Bolaget rörelsekapital, öka Bolagets finansiella flexibilitet och/eller att möjliggöra förvärv genom betalning med aktier. Om styrelsen beslutar om emission med avvikelse från aktieägarnas företrädesrätt ska skälet vara att tillföra Bolaget rörelsekapital på ett kostnads- och tidseffektivt sätt och/eller nya ägare av strategisk betydelse för Bolaget och/eller förvärv av andra företag eller verksamheter.

Punkt 13 – Beslut om (a) ändring av bolagsordningen samt (b) minskning av aktiekapitalet för avsättning till fritt eget kapital

Styrelsen föreslår att stämman beslutar om (a) ändring av gränserna för aktiekapitalet i bolagsordningen samt (b) minskning av Bolagets aktiekapital enligt nedan. Förslagen ska anses som ett förslag och därför antas av bolagsstämman som ett och samma beslut.

(a) Ändring av gränserna för aktiekapitalet i bolagsordningen
Styrelsen föreslår att bolagsstämman beslutar om ändring av gränserna för aktiekapitalet i bolagsordningens § 4 från ”lägst 50 000 000 kronor och högst 200 000 000 kronor” till ”lägst 15 000 000 kronor och högst 60 000 000 kronor”.

(b) Minskning av aktiekapitalet för avsättning till fritt eget kapital
Styrelsen föreslår att bolagsstämman beslutar om minskning av Bolagets aktiekapital, som för närvarande uppgår till 62 037 234,20 kronor, i enlighet med villkoren nedan:

Ändamålet med minskningen är avsättning till fritt eget kapital.
Bolagets aktiekapital ska minskas med 46 527 925,65 kronor.
Minskningen ska genomföras utan indragning av aktier.
Beslutet förutsätter ändring av bolagsordningen enligt punkt (a) ovan.

Styrelsen anser att ett lägre kvotvärde är mer ändamålsenligt för Bolagets aktiekapitalstruktur. Efter minskningen av aktiekapitalet kommer Bolagets aktiekapital att uppgå till 15 509 308,55 kronor, fördelat på sammanlagt 310 186 171 aktier, varav 600 000 A-aktier som ger rätt till tio (10) röster per aktie på bolagsstämma och 309 586 171 B-aktier som ger rätt till en (1) röst per aktie på bolagsstämma. Samtliga aktier kommer efter minskningen att ha ett kvotvärde om 0,05 kronor per aktie.

Beslutet om att minska Bolagets aktiekapital i enlighet med detta förslag kräver tillstånd från Bolagsverket eller allmän domstol.

Punkt 14 – Beslut om bemyndigande till styrelsen att vidta mindre justeringar av de på stämman fattade besluten

Styrelsen föreslår att stämman bemyndigar styrelsen, den verkställande direktören eller den styrelsen i övrigt förordnar att vidta sådana smärre justeringar och förtydliganden av de på stämman fattade besluten i den utsträckning detta är erforderligt för registrering av besluten.

ÖVRIGT

Majoritetskrav

För giltigt beslut enligt förslag till beslut enligt punkterna 12 och 13 krävs att det biträds av aktieägare med minst två tredjedelar (2/3) av såväl de avgivna rösterna som de aktier som är företrädda vid bolagsstämman.

Aktieägares rätt att begära upplysningar

Aktieägare har av styrelsen och den verkställande direktören rätt begära upplysningar enligt 7 kap. 32 § aktiebolagslagen avseende förhållanden som kan inverka på bedömningen av ett ärende på dagordningen eller som kan inverka på bedömningen av bolagets ekonomiska situation. Styrelsen och den verkställande direktören ska lämna ut sådana upplysningar om styrelsen anser att det kan ske utan väsentlig skada för Bolaget.

Handlingar

Kallelsen, styrelsens fullständiga förslag till beslut, fullmaktsformulär samt redovisningshandlingar och revisionsberättelse för år 2024 och övriga handlingar enligt aktiebolagslagen kommer hållas tillgängliga för aktieägare hos Bolaget tre veckor före stämman samt sändas kostnadsfritt till de aktieägare som begär det och uppger sin postadress. Handlingarna kommer också publiceras på Bolagets hemsida (www.izafegroup.com), senast samma dag.

Behandling av personuppgifter

För information om hur dina personuppgifter behandlas i samband med bolagsstämman, se integritetspolicyn på Euroclear AB:s webbplats,

www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf.

Antal aktier och röster

Det totala antalet aktier i Bolaget uppgår per dagen för denna kallelse till 310 186 171, varav 600 000 A-aktier och 309 586 171 B-aktier. Det totala antalet röster i Bolaget uppgår till 315 586 171 röster där varje A-aktie berättigar till tio (10) röster och varje B-aktie berättigar till en (1) röst.

Stockholm i april 2025

iZafe Group AB

Styrelsen

Om iZafe Group AB (publ.)

iZafe Group är ett Life Science bolag som bedriver forskning, utveckling och marknadsföring av digitala medicinska lösningar och tjänster för tryggare läkemedelshantering i hemmet.

Bolaget leder utvecklingen av digital läkemedelsdispensering genom läkemedelsroboten Dosell samt SaaS-lösningen och den uppkopplade dosettasken Pilloxa. Bolagets lösningar minskar risken för felmedicinering i hemmet, ökar följsamheten, avlastar den offentliga vården, ökar livskvaliteten för patienter samt skapar en tryggare miljö för anhöriga.

Kunderna utgörs av privatpersoner, läkemedelsbolag samt offentliga och privata vårdgivare i Sverige, Norden och globalt. iZafe Group säljer primärt via väletablerade partners som redan besitter långa och djupa kundrelationer med de prioriterade kundgrupperna. Huvudkontoret ligger i Stockholm.

iZafe Group AB är noterat på Nasdaq First North Growth Market sedan 2018. Bolagets Certified Adviser är Carnegie Investment Bank AB (publ). Ytterligare information finns på www.izafegroup.com

KALLELSE TILL ÅRSSTÄMMA I IZAFE GROUP AB

Izafegroup Primarylogo Lightbg

iZafe Group Q1 Interim Report, January-March 2025

iZafe Group AB (publ.) presents today, April 25th, its report for the first quarter.

Financial Performance in Summary

Total net revenue for the quarter amounted to 1,318 TSEK (3,410), now primarily consisting of recurring license revenues. This contrasts with the same period last year, when revenue was mainly driven by hardware sales, which in turn enable the generation of these recurring license revenues.
Operating result (EBIT) for the quarter amounted to -3,519 TSEK (-5,569).
Operating result before depreciation and amortization (EBITDA) for the quarter amounted to -2,538 TSEK (-4,588), a clear improvement despite lower revenue compared to the same period last year. This reflects a more profitable revenue mix and increased operational efficiency.
Result after financial items for the quarter amounted to -3,779 TSEK (-5,609).
Cash flow from operating activities for the quarter amounted to -7,013 TSEK (-4,109).
Earnings per share for the quarter before/after dilution amounted to -0.01 SEK (-0.02).
Equity per share at the end of the period amounted to 0.04 SEK (0.08).
The equity ratio at the end of the period was 53.2% (67.5%).

Significant events during the quarter

iZafe Group has completed a directed share issue of approximately SEK 9.2 million through the issuance of 46.15 million B-shares at a subscription price of SEK 0.20 per share. The capital will be used to strengthen working capital, accelerate growth, and support the expansion of Dosell and Pilloxa into new markets.
iZafe Group AB has initiated the sales of Dosell in Spain through its partnership with Ti-Medi. The product is launched under the Savioo Home brand and is now available through Ti-Medi’s network of over 1,500 pharmacies. Dosell enables automatic reminders and alerts in case of missed medication, improving adherence and safety for patients and their families. The launch marks an important milestone in iZafe Group’s international expansion.
iZafe Group AB has entered into an agreement with Carnegie Investment Bank AB as its new Certified Adviser. Carnegie will assume the role on April 1, 2025, and until then, Mangold Fondkommission AB will continue to serve as the company’s Certified Adviser.

Significant events after the end of the quarter

iZafe Group AB has continued to grow during the quarter with an increase in billable Dosell units and strong demand in Sweden, the Netherlands, and Spain. Three new municipalities have initiated operations, the partner TCCN is launching Dosell TV in the Netherlands, and over 50 pharmacies in Spain have joined the Savioo Home concept. The company is experiencing growing commercial momentum and is engaged in discussions with new partners for continued expansion.

Forecast
In this report, we present a forecast graph illustrating our expected growth in both ARR and active Dosell units over the coming years. The forecast is based on our current markets and key performance indicators, outlining a clear path toward an exponential increase in recurring revenue as more units become activated. By the end of 2024, our ARR reached approximately 1.7 MSEK, reflecting a 326% increase compared to the previous year.

In 2025, this growth is expected to accelerate further, with ARR projected to reach 10 MSEK by year-end, a 352% increase. Beyond that, ARR is expected to continue growing rapidly, more than eightfold by 2029, when we anticipate exceeding 85 MSEK. We will track this forecast on a quarterly basis to provide our shareholders with a clear view of our actual progress and how we are advancing toward our financial goals.

	2023	2024	2025	2026	2027	2028	2029
ARR (MSEK)	0.3	1.7	10	22.5	42.3	63.9	85.5
Growth of Dosells	0%	467%	488%	125%	88%	51%	34%

Comments from the CEO
2025 has started strong for iZafe Group, and we are now entering the next phase of our growth journey. We can clearly see how previous deliveries of Dosell to our partners are now bearing fruit in the form of recurring license revenues – the most profitable part of our business model. Our focus on scalability, recurring revenues, and international expansion is beginning to show tangible financial results.

During the first quarter, the number of active Dosell units has continued to grow rapidly. It is now – as these units are activated and used daily – that we are realizing the value of the investments and deliveries made throughout 2024. Our ARR at the end of the quarter surpassed 3 MSEK, confirming that we are on track to meet our financial targets for the year. This development is fully in line with the growth forecast we presented in the previous quarterly report and clearly shows that our business model is scaling as expected.

The shift towards recurring revenues improves profitability

Even though net revenue in Q1 2025 (1.3 MSEK) is lower than the corresponding quarter last year, the result has improved significantly. This is thanks to a larger share of revenues now being license-based with high margins – a direct effect of the increased activation rate among our partners. Operating profit improved by more than 2 MSEK compared to Q1 2024, providing clear evidence that our strategy is working.

We have now established a recurring revenue model that is scalable, predictable, and profitable. As more Dosell units are activated, revenues grow without a corresponding increase in the cost base – a powerful shift that lays the foundation for cash flow positivity and long-term profitability.

Momentum across multiple markets

During Q1, we have continued to increase our presence and demand in our key markets:

– Sweden: We have now launched Dosell in 14 new municipalities so far this year, with several more in the pipeline. An increasing number of municipalities are moving from pilot projects to full implementation, demonstrating that we have found the right fit in both product and offering. Demand is driven by safety, simplicity, and increased efficiency in home care services.

– Netherlands: Our partner TCCN has reported continued strong activation rates, including 72 units delivered to their customer MobileCare during March. The launch of Dosell TV and exposure at trade fairs are creating additional momentum. The Netherlands is now a mature growth market for us.

– Spain: Our Spanish partner Ti-Medi has officially launched Dosell as part of its Savioo platform. Over 50 pharmacies have already joined the concept. This gives us access to a rapidly growing market with a high proportion of dose pouch users and strong demand for digital solutions.

Strengthened liquidity after the end of the quarter

At the end of the quarter, cash and cash equivalents amounted to approximately 0.7 MSEK, reflecting the investments we have made to accelerate our expansion. However, it is important to highlight that half of the previously communicated directed share issue of approximately 9.2 MSEK was received by the company in April. This means that our cash position has been significantly strengthened after the period, creating better conditions to continue executing our growth plan.

Focus on real impact – and what truly matters

We now have strong momentum in the business, with the number of Dosell units loaded with medication and dispensing daily increasing month by month. This development forms the foundation for both our long-term growth and the societal benefit we aim to deliver.

Our most important key metric is not simply how many units we have sold or are billing licenses for, but how many times we have ensured correct medication. So far, we have surpassed over 400,000 doses dispensed at the right time – each dose representing a moment of safety for the user, reduced strain on healthcare providers, and improved adherence.

A new phase – moving full speed ahead

In a short time, we have established a product that is in demand, a scalable business model, and a clear growth strategy. During the quarter, we have further improved the product with a new software version, maintained our cost focus, and strengthened our customer relationships. The momentum we now see – both in actual usage and business development – is clear evidence that something has shifted.

In parallel, we continue to engage in discussions with new potential partners, both in existing and new markets, with the aim of expanding our presence and reaching more patients through the right local collaborations.

We are entering a breakthrough year where the focus is on continuing to scale, streamline operations, and create value – for our users, partners, society, and our shareholders.

Thank you to all employees, partners, and shareholders who make this journey possible.

Anders Segerström
Chief Executive Officer, iZafe Group

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

Interim Report Q1 2025

CEO interview

Q1 2025 Bild